EUVIMEDEUVIMED entdecken
Crossref

Identification of Alkaloid-Derived α-Glucosidase Inhibitors for Diabetes Management: An In Silico Approach

Mohsen Keshtmand, Morteza Sadeghi

Journal of Advanced Biomedical Sciences · 31.05.2026

DOI: 10.18502/jabs.v16i3.21625 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Advanced Biomedical Sciences, online erschienen am 31.05.2026. Verfasst von Mohsen Keshtmand und 1 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background & Objectives: Alkaloids constitute a structurally diverse class of naturally occurring compounds with a wide range of pharmacological activities. One of the principal mechanisms through which alkaloids may contribute to the management of diabetes mellitus (DM) is the inhibition of α-glucosidase. Despite their considerable therapeutic potential, the molecular interactions between alkaloids and α-glucosidase remain insufficiently characterized and warrant comprehensive investigation. Therefore, this study aimed to identify potential alkaloid-derived α-glucosidase inhibitors using an in silico approach for the management of DM. Materials & Methods: An initial computational screening of 15 alkaloid ligands excluded cepharanthine because of predicted mutagenicity and immunotoxicity, whereas tetrandrine and fangchinoline were excluded because they failed to satisfy drug-likeness criteria. The remaining 12 compounds were subsequently subjected to molecular docking against α-glucosidase.

Results

Scopolamine exhibited the most favorable docking score (-6.91 kcal/mol), outperforming acarbose, the reference inhibitor (-6.87 kcal/mol). In the α-glucosidase and scopolamine complex, Arg699 and Glu301 participated in hydrogen bond and Pi anion interactions, respectively. Secondary structure analysis further revealed scopolamine induced conformational alterations in α-glucosidase, characterized by an increase in α-helix content and a reduction in β-sheet content, changes that were consistent with its predicted inhibitory activity.

Conclusion

These findings suggest that scopolamine is a promising candidate α-glucosidase inhibitor. Nevertheless, further in vitro and in vivo studies are required to validate its antidiabetic potential and determine its therapeutic value for controlling postprandial hyperglycemia in DM

Zitieren

APA

Keshtmand, M., & Sadeghi, M. (2026). Identification of Alkaloid-Derived α-Glucosidase Inhibitors for Diabetes Management: An In Silico Approach. Journal of Advanced Biomedical Sciences. https://doi.org/10.18502/jabs.v16i3.21625

Vancouver

Keshtmand M, Sadeghi M. Identification of Alkaloid-Derived α-Glucosidase Inhibitors for Diabetes Management: An In Silico Approach. Journal of Advanced Biomedical Sciences. 2026. doi:10.18502/jabs.v16i3.21625

BibTeX
@article{Keshtmand2026,
  author = {Keshtmand, Mohsen and Sadeghi, Morteza},
  title = {Identification of Alkaloid-Derived α-Glucosidase Inhibitors for Diabetes Management: An In Silico Approach},
  journal = {Journal of Advanced Biomedical Sciences},
  year = {2026},
  doi = {10.18502/jabs.v16i3.21625}
}
Kostenlos starten →